Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC raised its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 6.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 438,083 shares of the biopharmaceutical company’s stock after purchasing an additional 26,600 shares during the quarter. TimesSquare Capital Management LLC owned 0.41% of Intra-Cellular Therapies worth $32,055,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Covestor Ltd raised its stake in shares of Intra-Cellular Therapies by 40.4% during the 3rd quarter. Covestor Ltd now owns 1,811 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 521 shares during the last quarter. Atria Investments Inc grew its holdings in Intra-Cellular Therapies by 41.1% during the third quarter. Atria Investments Inc now owns 5,137 shares of the biopharmaceutical company’s stock worth $376,000 after acquiring an additional 1,497 shares during the period. Assetmark Inc. raised its position in Intra-Cellular Therapies by 9.1% during the third quarter. Assetmark Inc. now owns 2,477 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 207 shares in the last quarter. Capital Performance Advisors LLP purchased a new position in Intra-Cellular Therapies during the third quarter valued at approximately $74,000. Finally, Quantum Private Wealth LLC lifted its holdings in Intra-Cellular Therapies by 1.0% in the third quarter. Quantum Private Wealth LLC now owns 38,661 shares of the biopharmaceutical company’s stock valued at $2,829,000 after acquiring an additional 400 shares during the period. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Analysts Set New Price Targets

ITCI has been the topic of a number of analyst reports. Piper Sandler raised shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $68.00 to $92.00 in a research note on Friday, September 6th. Cantor Fitzgerald restated an “overweight” rating and set a $130.00 price target on shares of Intra-Cellular Therapies in a research report on Monday, September 16th. The Goldman Sachs Group decreased their price objective on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Morgan Stanley increased their target price on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday, October 30th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $97.23.

Intra-Cellular Therapies Trading Up 0.9 %

ITCI stock opened at $91.29 on Friday. The business’s 50-day moving average is $76.78 and its 200 day moving average is $73.77. The stock has a market cap of $9.68 billion, a price-to-earnings ratio of -104.93 and a beta of 0.97. Intra-Cellular Therapies, Inc. has a 12-month low of $52.88 and a 12-month high of $91.68.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The business had revenue of $175.40 million for the quarter, compared to analyst estimates of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business’s revenue was up 39.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.25) earnings per share. As a group, equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Insider Buying and Selling at Intra-Cellular Therapies

In other news, EVP Mark Neumann sold 18,714 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $75.08, for a total value of $1,405,047.12. Following the completion of the sale, the executive vice president now owns 29,700 shares of the company’s stock, valued at $2,229,876. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Intra-Cellular Therapies news, EVP Mark Neumann sold 18,714 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the completion of the transaction, the executive vice president now owns 29,700 shares of the company’s stock, valued at $2,229,876. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Sharon Mates sold 53,013 shares of Intra-Cellular Therapies stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $80,970,388.85. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 175,316 shares of company stock worth $13,037,345 in the last three months. 2.60% of the stock is owned by corporate insiders.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.